BioSpace News Archive

bioAffinity Technologies , a privately held biotech company, today announced it has closed a non-brokered, secured convertible note (“Note”) financing for proceeds of $5,000,000.00 (the “Offering”). The proceeds from the Note are funding operations to advance the Company’s non-invasive CyPath® Lung cancer test and therapeutic research and development of novel drug candidates for the selective treatment of multiple cancers.

MJH Life Sciences™ today announced it will host “COVID-19: Race for a Vaccine,” a free, live, one-hour webinar, Thursday, July 30, at 6 p.m. EDT.

BioTheryX, Inc., a clinical stage biotechnology company harnessing the power of protein modulation to treat difficult diseases, today announced it has closed a $35 million Series D financing. The round was led by MSD Partners, L.P. “We are pleased to have closed this financing that will enable us to accelerate expansion of our ongoin

As part of a long-standing partnership, Tiger Woods details his patient journey from debilitating back pain to his recovery and return to active life.

Second Phase of the Code Life Ventilator Challenge: Solvers Will Win up to $300K to Develop Regulatory-Approved Ventilator Production Package for Less Than $1K

Biotech incubator FutuRx ltd., today announced that Leaps by Bayer, the impact investments unit of Bayer AG, will join FutuRx as an investor for incepting and incubating early stage biotech companies. Both Leaps by Bayer and FutuRx invest in paradigm-shifting technologies in the life sciences, aiming to change the world for the

Zavation Medical Products (“Zavation” or the “Company”), an innovative designer and manufacturer of high-quality spinal implants, instruments, MIS procedural kits, and biologics headquartered in Flowood, MS , announced the launch of both the Expandable Anterior Lumbar Plate and the Expandable Lateral Lumbar Plate, plates designed for

Purdue Pharma (Canada) announces the results from two studies that independently evaluated in vitro virucidal activity of BETADINE® povidone-iodine (PVP-I). The studies found BETADINE® PVP-I killed 99.99% of the SARS-CoV-2 virus, which causes COVID-19, in 30 seconds or less.

Life sciences professionals are confident in their job security despite the economy, according to a new survey by global recruiter EPM Scientific. 50% of US respondents and 59% of European respondents feel confident in keeping their jobs over the next six months, despite the majority predicting a worsening economy over the next year.

Davidson Kempner European Partners, LLP is the sub-adviser to Davidson Kempner Capital Management LP which acts as the discretionary investment manager to various funds which represent 5.1% of the share capital of QIAGEN N.V. (the “Company”)